title: [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
authors.affiliation: Actelion pharmaceuticals France SAS, 75001 Paris, France.
authors.forename: Annick
authors.initials: A
authors.lastname: Schwebig
authors.forename: Christophe
authors.initials: C
authors.lastname: Duguet
authors.forename: Antoine
authors.initials: A
authors.lastname: Ferry
authors.forename: Claude
authors.initials: C
authors.lastname: Bougé
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Fagon
authors.forename: Catherine
authors.initials: C
authors.lastname: Bismuth
authors.forename: Jacques
authors.initials: J
authors.lastname: Ramon
mesh_terms: D003362:Cost-Benefit Analysis; D003627:Data Interpretation, Statistical; D030881:Disclosure / Q000639:trends*; D004345:Drug Industry / Q000191:economics / Q000941:ethics / Q000379:methods; D005252:Fees, Pharmaceutical; D017048:Health Care Costs; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy* / Q000191:economics*
chemical_list: D004364:Pharmaceutical Preparations